Lymphangitis carcinomatosa: Difference between revisions
Jump to navigation
Jump to search
| (63 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{Swathi}} | {{CMG}}; {{Swathi}} {{S.G.}} | ||
{{SK}} Lymphangitis carcinomatosis; Pulmonary lymphangitic carcinomatosis | {{SK}} Lymphangitis carcinomatosis; Pulmonary lymphangitic carcinomatosis | ||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
[[Lymphangitis|Lymphangitis carcinomatosa]] also known as carcinomatous [[lymphangitis]], is an [[inflammation]] of the [[lymph vessel]]s [[secondary]] to a [[malignancy]]. [[Lymphangitis]] carcinomatosa was first discovered by Gabriel Andral, a French [[Pathologists|pathologist]], in 1829. The [[pathogenesis]] of [[lymphangitis]] carcinomatosa is characterized by the [[tumoral]] [[Spread of the cancer|spread]] into the [[lymphatics]], following hematogenous seeding of the [[lungs]]. The [[pathogenesis]] is also characterized by [[Retrograde infection|retrograde]] [[Spread of the cancer|spread]] into [[lymphatics]] from the [[mediastinal]] and [[hilar]] [[lymph nodes]] in the lungs. Common [[causes]] of [[lymphangitis]] carcinomatosa include [[breast cancer]] (most common), [[lung cancer]], [[Colorectal cancer|colon cancer]], [[stomach cancer]], [[prostate cancer]], [[cervical cancer]], and [[thyroid cancer]]. [[Lymphangitis]] carcinomatosa is a [[rare]] [[disease]]. The [[prevalence]] of [[lymphangitis]] carcinomatosa is approximately 0.03 per 100,000 individuals worldwide. [[Lymphangitis]] carcinomatosa is more commonly observed among [[patients]] [[Age|aged]] between 40 to 49 years old. [[Computed tomography]] is the [[imaging]] modality of choice for [[lymphangitis]] carcinomatosa. On [[CT-scans|CT]], characteristic findings of [[lymphangitis]] carcinomatosa include subpleural [[nodules]], thickening on the interlobar [[fissures]], [[pleural effusion]], and [[hilar]] and [[mediastinal]] [[Lymph node|nodal]] enlargement (40-50%). The mainstay [[therapy]] for [[lymphangitis]] carcinomatosa is [[systemic]] [[chemotherapy]] ([[Chemotherapeutic agent|chemotherapeutic]] regimen depends on the [[tumor]] [[histology]]). | [[Lymphangitis|Lymphangitis carcinomatosa]] also known as carcinomatous [[lymphangitis]], is an [[inflammation]] of the [[lymph vessel]]s [[secondary]] to a [[malignancy]]. [[Lymphangitis]] carcinomatosa was first discovered by Gabriel Andral, a French [[Pathologists|pathologist]], in 1829. The [[pathogenesis]] of [[lymphangitis]] carcinomatosa is characterized by the [[tumoral]] [[Spread of the cancer|spread]] into the [[lymphatics]], following hematogenous seeding of the [[lungs]]. The [[pathogenesis]] is also characterized by [[Retrograde infection|retrograde]] [[Spread of the cancer|spread]] into [[lymphatics]] from the [[mediastinal]] and [[hilar]] [[lymph nodes]] in the [[Lung|lungs]]. Common [[causes]] of [[lymphangitis]] carcinomatosa include [[breast cancer]] (most common), [[lung cancer]], [[Colorectal cancer|colon cancer]], [[stomach cancer]], [[prostate cancer]], [[cervical cancer]], and [[thyroid cancer]]. [[Lymphangitis]] carcinomatosa is a [[rare]] [[disease]]. The [[prevalence]] of [[lymphangitis]] carcinomatosa is approximately 0.03 per 100,000 individuals worldwide. [[Lymphangitis]] carcinomatosa is more commonly observed among [[patients]] [[Age|aged]] between 40 to 49 years old. [[Computed tomography]] is the [[imaging]] modality of choice for [[lymphangitis]] carcinomatosa. On [[CT-scans|CT]], characteristic findings of [[lymphangitis]] carcinomatosa include subpleural [[nodules]], thickening on the interlobar [[fissures]], [[pleural effusion]], and [[hilar]] and [[mediastinal]] [[Lymph node|nodal]] enlargement (40-50%). The mainstay [[therapy]] for [[lymphangitis]] carcinomatosa is [[systemic]] [[chemotherapy]] ([[Chemotherapeutic agent|chemotherapeutic]] regimen depends on the [[tumor]] [[histology]]). | ||
==Historical Perspective== | ==Historical Perspective== | ||
*[[Lymphangitis]] carcinomatosa was first discovered by Gabriel Andral, a distinguished French [[pathologist]] | *[[Lymphangitis]] carcinomatosa was first discovered by Gabriel Andral, a distinguished French [[pathologist]] and professor at the University of Paris in 1829.<ref name="Doyle2018">{{cite journal|last1=Doyle|first1=L|title=Gabriel Andral (1797-1876) and the First Reports of Lymphangitis Carcinomatosa|journal=Journal of the Royal Society of Medicine|volume=82|issue=8|year=2018|pages=491–493|issn=0141-0768|doi=10.1177/014107688908200814}}</ref> | ||
*Andral's [[case report]] on [[postmortem]] findings of [[lymphangitis]] carcinomatosa followed after a [[case report]] on a [[Women|woman]] who had died from [[cancer]] of the [[uterus]]; there had been extensive [[Spread of the cancer|spread]] of the [[cancer]] in the [[pelvis]], [[mesentery]] and [[thoracic duct]]-there was no mention of [[pulmonary]] or [[pleural]] involvement.<ref name="Doyle20182">{{cite journal|last1=Doyle|first1=L|title=Gabriel Andral (1797-1876) and the First Reports of Lymphangitis Carcinomatosa|journal=Journal of the Royal Society of Medicine|volume=82|issue=8|year=2018|pages=491–493|issn=0141-0768|doi=10.1177/014107688908200814}}</ref> | |||
*Andral is remembered for his pioneer investigations of [[blood]] [[chemistry]]. | |||
*Gabriel Andral is considered to be the founder of [[scientific]] [[hematology]], and is credited with its integration into [[clinical]] and [[Analytical chemistry|analytical]] [[medicine]]. | |||
==Classification== | ==Classification== | ||
*There is no | *There is no established system for the classification of lymphangitis carcinomatosa.<ref name="pmid31245208">{{cite journal |vauthors=Aslam HM, Zhi C, Nadeem M, Arsalan M, Wallach SL |title=A Case of Rapidly Deteriorating Lymphangitic Carcinomatosis in a Patient with Stage IV Pancreatic Cancer |journal=Cureus |volume=11 |issue=4 |pages=e4421 |date=April 2019 |pmid=31245208 |pmc=6559437 |doi=10.7759/cureus.4421 |url=}}</ref> | ||
==Pathophysiology== | ==Pathophysiology== | ||
* | *It is understood that lymphangitis carcinomatosa is the result of the [[tumoral]] [[Spread of the cancer|spread]] into the [[lymphatics]], following [[Hematogen|hematogenous]] seeding of the [[lungs]].<ref name="BiswasSriram2015">{{cite journal|last1=Biswas|first1=Abhishek|last2=Sriram|first2=Peruvemba S.|title=Getting the Whole Picture: Lymphangitic Carcinomatosis|journal=The American Journal of Medicine|volume=128|issue=8|year=2015|pages=837–840|issn=00029343|doi=10.1016/j.amjmed.2015.04.007}}</ref> | ||
*The [[pathogenesis]] is also characterized by retrograde [[Spread of the cancer|spread]] into [[lymphatics]] from the [[mediastinal]] and [[hilar]] [[lymph nodes]] in the [[lungs]]. | *The [[pathogenesis]] is also characterized by retrograde [[Spread of the cancer|spread]] into [[lymphatics]] from the [[mediastinal]] and [[hilar]] [[lymph nodes]] in the [[lungs]].<ref name="Beattie1956">{{cite journal|last1=Beattie|first1=J.W.|title=Lymphangitis carcinomatosa|journal=British Journal of Tuberculosis and Diseases of the Chest|volume=50|issue=2|year=1956|pages=120–129|issn=03660869|doi=10.1016/S0366-0869(56)80046-4}}</ref> | ||
*There are no specific [[genetic]] [[mutations]] associated with the [[development]] of | *Both the peripheral [[lymphatics]] coursing in the interlobular [[septa]] and beneath the [[pleura]], and the central [[lymphatics]] coursing in the bronchovascular [[interstitium]] are involved.<ref name="urlLymphangitic carcinomatosis | Radiology Reference Article | Radiopaedia.org">{{cite web |url=https://radiopaedia.org/articles/lymphangitic-carcinomatosis?iframe=true&lang=us |title=Lymphangitic carcinomatosis | Radiology Reference Article | Radiopaedia.org |format= |work= |accessdate=}}</ref> | ||
*There are no specific [[genetic]] [[mutations]] associated with the [[development]] of lymphangitis carcinomatosa.<ref name="MoubaxWuyts2012">{{cite journal|last1=Moubax|first1=Kim|last2=Wuyts|first2=Wim|last3=Vandecaveye|first3=Vincent|last4=Prenen|first4=Hans|title=Pulmonary lymphangitic carcinomatosis as a primary manifestation of gastric carcinoma in a young adult: a case report and review of the literature|journal=BMC Research Notes|volume=5|issue=1|year=2012|pages=638|issn=1756-0500|doi=10.1186/1756-0500-5-638}}</ref> | |||
*On [[gross pathology]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis</ref> | *On [[gross pathology]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis</ref> | ||
:*No remarkable findings | :*No remarkable findings | ||
*On [[microscopic]] [[histopathological]] [[analysis]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis Accesed on April 29, 2016</ref> | *On [[microscopic]] [[histopathological]] [[analysis]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis Accesed on April 29, 2016</ref> | ||
:*[[Carcinoma]] in multiple the [[lymphatic]] channels | :*[[Carcinoma]] in multiple the [[lymphatic]] channels | ||
[[File:Metastatic gastric adenocarcinoma-lymphangitic carcinomatosis (7261944992).jpg|300px|thumb|none|Poorly differentiated adenocarcinoma within lymphatics surrounding an artery. Yale Rosen from USA [CC BY-SA 2.0 (https://creativecommons.org/licenses/by-sa/2.0)],https://upload.wikimedia.org/wikipedia/commons/3/34/Metastatic_gastric_adenocarcinoma-lymphangitic_carcinomatosis_%287261944992%29.jpg,https://commons.wikimedia.org/wiki/File:Metastatic_gastric_adenocarcinoma-lymphangitic_carcinomatosis_(7261944992).jpg]] | |||
==Causes== | ==Causes== | ||
| Line 35: | Line 40: | ||
==Differentiating Lymphangitis Carcinomatosa from Other Diseases== | ==Differentiating Lymphangitis Carcinomatosa from Other Diseases== | ||
*[[Lymphangitis]] carcinomatosa must be [[Differentiate|differentiated]] from other [[diseases]] that cause thickened [[interlobular]] [[septa]]e (on imaging finding), [[dyspnea]], [[fatigue]], and [[weight-loss]], such as: | *[[Lymphangitis]] carcinomatosa must be [[Differentiate|differentiated]] from other [[diseases]] that cause thickened [[interlobular]] [[septa]]e (on imaging finding), [[dyspnea]], [[fatigue]], and [[weight-loss]], such as:<ref name="ThomasLenox2008">{{cite journal|last1=Thomas|first1=A.|last2=Lenox|first2=R.|title=Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult|journal=Canadian Medical Association Journal|volume=179|issue=4|year=2008|pages=338–340|issn=0820-3946|doi=10.1503/cmaj.080142}}</ref><ref name="AslamZhi2019">{{cite journal|last1=Aslam|first1=Hafiz M|last2=Zhi|first2=Cassandra|last3=Nadeem|first3=Muhammad|last4=Arsalan|first4=Mohammad|last5=Wallach|first5=Sara L|title=A Case of Rapidly Deteriorating Lymphangitic Carcinomatosis in a Patient with Stage IV Pancreatic Cancer |journal=Cureus|year=2019|issn=2168-8184|doi=10.7759/cureus.4421}}</ref> | ||
:*[[Sarcoidosis]] | :*[[Sarcoidosis]] | ||
:*[[Viral pneumonia]] | :*[[Pulmonary]] [[Alveolar]] [[Protein|Proteinosis]] | ||
:*[[Viral pneumonia]]; [[pneumocystis jirovecii]] | |||
:*[[Pulmonary edema]] | :*[[Pulmonary edema]] | ||
:*[[Pneumonitis|Radiation pneumonitis]] | :*[[Pneumonitis|Radiation pneumonitis]] | ||
:*[[Lymphocytic]] [[interstitial pneumonitis]] | :*[[Lymphocytic]] [[interstitial pneumonitis]] | ||
*[[Pulmonary]] lymphangitic carcinomatosis occurs in 6%–8% of [[Patient|patients]] with [[pulmonary]] [[Metastasis|metastases]].<ref name="ThomasLenox20082">{{cite journal|last1=Thomas|first1=A.|last2=Lenox|first2=R.|title=Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult|journal=Canadian Medical Association Journal|volume=179|issue=4|year=2008|pages=338–340|issn=0820-3946|doi=10.1503/cmaj.080142}}</ref> | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* | *Lymphangitis carcinomatosa is a [[rare]] [[disease]].<ref name="KashiharaKanai2018">{{cite journal|last1=Kashihara|first1=Eriko|last2=Kanai|first2=Osamu|last3=Okamura|first3=Misato|last4=Mio|first4=Tadashi|title=Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome|journal=BMJ Case Reports|year=2018|pages=bcr-2018-224206|issn=1757-790X|doi=10.1136/bcr-2018-224206}}</ref> | ||
*The [[prevalence]] of | *The [[prevalence]] of lymphangitis carcinomatosa is approximately 0.03 per 100,000 individuals worldwide.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
===Age=== | ===Age=== | ||
| Line 53: | Line 61: | ||
===Gender=== | ===Gender=== | ||
*[[ | *The condition affects [[males]] more than the [[Female|females]] | ||
*Affects a younger [[population]] than that affected with most [[malignancies]] | |||
===Race=== | ===Race=== | ||
*There is no [[racial]] predilection for | *There is no [[racial]] predilection for lymphangitis carcinomatosa. | ||
==Risk Factors== | ==Risk Factors== | ||
*Common [[risk factors]] in the [[development]] of | *Common [[risk factors]] in the [[development]] of lymphangitis carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
:*Personal [[History and Physical examination|history]] of [[cancer]] | :*Personal [[History and Physical examination|history]] of [[cancer]] | ||
:*Preexistent [[malignant]] [[cancer]] | :*Preexistent [[malignant]] [[cancer]] | ||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
*The majority of [[patients]] with [[lymphangitis]] carcinomatosa are [[symptomatic]] at the time of [[diagnosis]]. | *The majority of [[patients]] with [[lymphangitis]] carcinomatosa are [[symptomatic]] at the time of [[diagnosis]].<ref name="RajaSeshadri2011">{{cite journal|last1=Raja|first1=Anand|last2=Seshadri|first2=Ramakrishnan Ayloor|last3=Sundersingh|first3=Shirley|title=Lymphangitis Carcinomatosa: Report of a Case and Review of Literature|journal=Indian Journal of Surgical Oncology|volume=1|issue=3|year=2011|pages=274–276|issn=0975-7651|doi=10.1007/s13193-011-0047-9}}</ref> | ||
*There are two [[Theory|theories]] as to how this [[condition]] occurs<ref name="KhachekianShargh2015">{{cite journal|last1=Khachekian|first1=Arsineh|last2=Shargh|first2=Sean|last3=Arabian|first3=Sarkis|title=Pulmonary Lymphangitic Carcinomatosis From Metastatic Gastric Adenocarcinoma: Case Report|journal=The Journal of the American Osteopathic Association|volume=115|issue=5|year=2015|pages=332|issn=0098-6151|doi=10.7556/jaoa.2015.064}}</ref> | |||
**The first [[theory]] states there is [[Haematogen|haematogenous]] [[metastasis]] producing [[Endarteritis obliterans|obliterative]] [[Endarteritis obliterans|endarteritis]] and then [[Tumor cell|tumor]] [[Cells (biology)|cells]] subsequently egress through [[vascular]] walls into the [[Perivascular cell|perivascular]] [[lymphatics]]. | |||
**The second [[theory]] states there may be [[diffuse]] retrograde permeation and [[embolization]] of [[lymphatics]] after involvement of the [[hilar]] [[Lymph nodes|lymph nodes.]] | |||
*Early [[clinical]] features include [[dyspnea]], [[fatigue]], and [[weight-loss]]. | *Early [[clinical]] features include [[dyspnea]], [[fatigue]], and [[weight-loss]]. | ||
*If left untreated, [[patients]] with | *Lymphangitis carcinomatosa may precede or obscure or dominate any local [[symptoms]] and present as a [[diagnostic]] problem in [[dyspnoea]].<ref name="JaswalAhuja2019">{{cite journal|last1=Jaswal|first1=Sofia|last2=Ahuja|first2=Vanita|last3=Aggarwal|first3=Deepak|last4=Kaur|first4=Harkirat|title=Incidental finding of pulmonary lymphangitis carcinomatosa in a patient of chest trauma|journal=Indian Journal of Anaesthesia|volume=63|issue=1|year=2019|pages=70|issn=0019-5049|doi=10.4103/ija.IJA_581_18}}</ref> | ||
*Common [[complications]] of | *Lymphangitis carcinomatosa may also occur during the evolution of a [[growth]], which has already been identified during [[life]], in which case [[diagnosis]] becomes relatively easier. | ||
*If left untreated, [[patients]] with lymphangitis carcinomatosa may progress to [[Development|develop]] acute [[respiratory failure]]. | |||
*Common [[complications]] of lymphangitis carcinomatosa include:<ref name="ThomasLenox2008" /> | |||
:*[[Pulmonary embolism D-dimer|Pulmonary tumor embolism]] | :*[[Pulmonary embolism D-dimer|Pulmonary tumor embolism]] | ||
:*[[Pulmonary hypertension]] | :*[[Pulmonary hypertension]] | ||
*[[Prognosis]] is generally poor, and the [[mean]] [[survival rate]] of [[patients]] after [[diagnosis]] of [[lymphangitis]] carcinomatosa is approximately 6 months. | *[[Prognosis]] is generally poor, and the [[mean]] [[survival rate]] of [[patients]] after [[diagnosis]] of [[lymphangitis]] carcinomatosa is approximately 6 months. | ||
*Approximately half of [[patients]] succumbing to their [[illness]] within a [[year]] of [[diagnosis]]. | |||
*Occasionally, long-term [[Survival rate|survival]] is encountered. | |||
== Diagnosis == | == Diagnosis == | ||
=== Symptoms === | === Symptoms === | ||
*[[ | *The majority of [[Patient|patients]] with lymphangitis carcinomatosa are [[asymptomatic]]. | ||
*Lymphangitis carcinomatosa is usually [[asymptomatic]].<ref name="RajaSeshadri20112">{{cite journal|last1=Raja|first1=Anand|last2=Seshadri|first2=Ramakrishnan Ayloor|last3=Sundersingh|first3=Shirley|title=Lymphangitis Carcinomatosa: Report of a Case and Review of Literature|journal=Indian Journal of Surgical Oncology|volume=1|issue=3|year=2011|pages=274–276|issn=0975-7651|doi=10.1007/s13193-011-0047-9}}</ref> | |||
*[[Symptoms]] of [[lymphangitis]] carcinomatosa may include the following:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | *[[Symptoms]] of [[lymphangitis]] carcinomatosa may include the following:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
:* [[Hemoptysis]] | |||
:*[[Hemoptysis]] | |||
:* [[Chronic (medical)|Chronic]] [[coughing]] | :* [[Chronic (medical)|Chronic]] [[coughing]] | ||
:* [[Chest pain]] | :* [[Chest pain]] | ||
:* Loss of | :*[[Loss of appetite]] | ||
:* [[Fatigue]] | :* [[Fatigue]] | ||
| Line 96: | Line 115: | ||
=== Laboratory Findings === | === Laboratory Findings === | ||
*There are no specific [[laboratory]] findings associated with [[ | *There are no specific [[laboratory]] findings associated with lymphangitis carcinomatosa.<ref name="GilchristAlton2011">{{cite journal|last1=Gilchrist|first1=F. J.|last2=Alton|first2=H.|last3=Brundler|first3=M.-A.|last4=Edwards|first4=L.|last5=Plunkett|first5=A.|last6=Rao|first6=S.|title=Pulmonary lymphangitic carcinomatosis presenting as severe interstitial lung disease in a 15-year-old female|journal=European Respiratory Review|volume=20|issue=121|year=2011|pages=208–210|issn=0905-9180|doi=10.1183/09059180.00000911}}</ref> | ||
*Even if [[Histology|histologically]] confirmed, the [[chest radiograph]] is normal in 30–50% of cases. | |||
===Imaging Findings=== | ===Imaging Findings=== | ||
*[[Computed tomography]] is the [[imaging]] [[modality]] of choice for | *[[Computed tomography]] is the [[imaging]] [[modality]] of choice for lymphangitis carcinomatosa.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
*The most important feature about [[CT scan]] is the detection of peripheral and central changes. | *The most important feature about [[CT scan]] is the detection of peripheral and [[central]] changes. | ||
*On [[CT]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | *On [[CT]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
:*Subpleural [[nodules]], and thickening on the interlobar [[fissures]] | |||
:*Subpleural [[nodules]], and thickening on the interlobar [[fissures]] | |||
:*[[Pleural effusion]] | :*[[Pleural effusion]] | ||
:*[[Hilar]] and [[mediastinal]] [[Nodule (medicine)|nodal]] enlargement (40-50%) | :*[[Hilar]] and [[mediastinal]] [[Nodule (medicine)|nodal]] enlargement (40-50%) | ||
:*Relatively little destruction of overall [[lung]] architecture | :*Relatively little destruction of overall [[lung]] architecture | ||
:*Involvement of the peripheral ([[interlobular]] [[septa]]) and central [[lymphatic]] [[Lymphatic System|system]] | :*Involvement of the peripheral ([[interlobular]] [[septa]]) and central [[lymphatic]] [[Lymphatic System|system]] | ||
:*Distribution of changes is [[variable]], but most are asymmetric and patchy | :*Distribution of changes is [[variable]], but most are asymmetric and [[Patching|patchy]] | ||
:*Usually [[bilateral]] (may be unilateral especially in cases of [[lung]] and [[breast cancer]]) | :*Usually [[bilateral]] (may be unilateral especially in cases of [[lung]] and [[breast cancer]]) | ||
*[[Radiographic]] [[Appearance|appearances]] can most easily be divided into those due to the involvement of the peripheral and central lymphatic [[Lymphatic system|system]].<ref name="MunnPadera2014">{{cite journal|last1=Munn|first1=Lance L.|last2=Padera|first2=Timothy P.|title=Imaging the lymphatic system|journal=Microvascular Research|volume=96|year=2014|pages=55–63|issn=00262862|doi=10.1016/j.mvr.2014.06.006}}</ref> | |||
*Involvement may be [[Diffuse|diffusely]] of both, or predominantly of one [[Compartments|compartment]] or the other. | |||
*[[Distribution of terms|Distribution]] of changes is [[variable]], but most are asymmetric and patchy; it is usually [[bilateral]] but may be unilateral, specifically in cases of [[Lung cancer|lung]] and [[breast cancer]].<ref name="AburtoHerráez2018">{{cite journal|last1=Aburto|first1=Myriam|last2=Herráez|first2=Inmaculada|last3=Iturbe|first3=David|last4=Jiménez-Romero|first4=Ana|title=Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis|journal=Medical Sciences|volume=6|issue=3|year=2018|pages=73|issn=2076-3271|doi=10.3390/medsci6030073}}</ref> | |||
[[File:Breast-cancer-with-lymphangitis-carcinomatosa.jpg|300px|thumb|none|Left breast mass, mediastinal lymphadenopathy and features of lymphangitis carcinomatosis. In addition scattered bony metastatic lesions are seen in dorsal vertebrae, Case courtesy of Dr Paresh K Desai , Radiopaedia.org, rID: 17917, Case courtesy of Dr Paresh K Desai , <a href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/17917">rID: 17917</a>]] | |||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
*The mainstay [[therapy]] for | *The mainstay [[therapy]] for lymphangitis carcinomatosa is [[systemic]] [[chemotherapy]] ([[chemotherapeutic]] [[Chemotherapy regimens|regimen]] depends on the [[tumor]] [[histology]]).<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
=== Surgery === | === Surgery === | ||
*[[Surgery]] is not recommended for [[patients]] with | *[[Surgery]] is not recommended for [[patients]] with lymphangitis carcinomatosa. | ||
=== Prevention === | === Prevention === | ||
*There are no primary [[Preventive medicine|preventive]] measures available for | *There are no primary [[Preventive medicine|preventive]] measures available for lymphangitis carcinomatosa. <ref name="BiswasSriram2015">{{cite journal|last1=Biswas|first1=Abhishek|last2=Sriram|first2=Peruvemba S.|title=Getting the Whole Picture: Lymphangitic Carcinomatosis|journal=The American Journal of Medicine|volume=128|issue=8|year=2015|pages=837–840|issn=00029343|doi=10.1016/j.amjmed.2015.04.007}}</ref> | ||
*Once [[Diagnose|diagnosed]] and successfully treated, [[patients]] with | *Once [[Diagnose|diagnosed]] and successfully treated, [[patients]] with lymphangitis carcinomatosa are followed-up periodically. | ||
*Follow-up [[testing]] may include [[Pulmonary function test|respiratory function tests]] and [[disease]] progression monitorization. | *Follow-up [[testing]] may include [[Pulmonary function test|respiratory function tests]] and [[disease]] progression monitorization. | ||
Latest revision as of 13:48, 31 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Swathi Venkatesan, M.B.B.S.[2] Sogand Goudarzi, MD [3]
Synonyms and keywords: Lymphangitis carcinomatosis; Pulmonary lymphangitic carcinomatosis
Overview
Lymphangitis carcinomatosa also known as carcinomatous lymphangitis, is an inflammation of the lymph vessels secondary to a malignancy. Lymphangitis carcinomatosa was first discovered by Gabriel Andral, a French pathologist, in 1829. The pathogenesis of lymphangitis carcinomatosa is characterized by the tumoral spread into the lymphatics, following hematogenous seeding of the lungs. The pathogenesis is also characterized by retrograde spread into lymphatics from the mediastinal and hilar lymph nodes in the lungs. Common causes of lymphangitis carcinomatosa include breast cancer (most common), lung cancer, colon cancer, stomach cancer, prostate cancer, cervical cancer, and thyroid cancer. Lymphangitis carcinomatosa is a rare disease. The prevalence of lymphangitis carcinomatosa is approximately 0.03 per 100,000 individuals worldwide. Lymphangitis carcinomatosa is more commonly observed among patients aged between 40 to 49 years old. Computed tomography is the imaging modality of choice for lymphangitis carcinomatosa. On CT, characteristic findings of lymphangitis carcinomatosa include subpleural nodules, thickening on the interlobar fissures, pleural effusion, and hilar and mediastinal nodal enlargement (40-50%). The mainstay therapy for lymphangitis carcinomatosa is systemic chemotherapy (chemotherapeutic regimen depends on the tumor histology).
Historical Perspective
- Lymphangitis carcinomatosa was first discovered by Gabriel Andral, a distinguished French pathologist and professor at the University of Paris in 1829.[1]
- Andral's case report on postmortem findings of lymphangitis carcinomatosa followed after a case report on a woman who had died from cancer of the uterus; there had been extensive spread of the cancer in the pelvis, mesentery and thoracic duct-there was no mention of pulmonary or pleural involvement.[2]
- Andral is remembered for his pioneer investigations of blood chemistry.
- Gabriel Andral is considered to be the founder of scientific hematology, and is credited with its integration into clinical and analytical medicine.
Classification
- There is no established system for the classification of lymphangitis carcinomatosa.[3]
Pathophysiology
- It is understood that lymphangitis carcinomatosa is the result of the tumoral spread into the lymphatics, following hematogenous seeding of the lungs.[4]
- The pathogenesis is also characterized by retrograde spread into lymphatics from the mediastinal and hilar lymph nodes in the lungs.[5]
- Both the peripheral lymphatics coursing in the interlobular septa and beneath the pleura, and the central lymphatics coursing in the bronchovascular interstitium are involved.[6]
- There are no specific genetic mutations associated with the development of lymphangitis carcinomatosa.[7]
- On gross pathology, characteristic findings of lymphangitis carcinomatosa include:[8]
- No remarkable findings
- On microscopic histopathological analysis, characteristic findings of lymphangitis carcinomatosa include:[8]
.jpg)
.jpg){kind=link}
Causes
Differentiating Lymphangitis Carcinomatosa from Other Diseases
- Lymphangitis carcinomatosa must be differentiated from other diseases that cause thickened interlobular septae (on imaging finding), dyspnea, fatigue, and weight-loss, such as:[9][10]
- Pulmonary lymphangitic carcinomatosis occurs in 6%–8% of patients with pulmonary metastases.[11]
Epidemiology and Demographics
- Lymphangitis carcinomatosa is a rare disease.[12]
- The prevalence of lymphangitis carcinomatosa is approximately 0.03 per 100,000 individuals worldwide.[13]
Age
- Patients of all age groups may develop lymphangitis carcinomatosa.
- Lymphangitis carcinomatosa is more commonly observed among patients aged 40–49 years old.[13]
- Lymphangitis carcinomatosa is more commonly observed among middle aged adults.
Gender
- The condition affects males more than the females
- Affects a younger population than that affected with most malignancies
Race
- There is no racial predilection for lymphangitis carcinomatosa.
Risk Factors
- Common risk factors in the development of lymphangitis carcinomatosa include:[13]
Natural History, Complications and Prognosis
- The majority of patients with lymphangitis carcinomatosa are symptomatic at the time of diagnosis.[14]
- There are two theories as to how this condition occurs[15]
- The first theory states there is haematogenous metastasis producing obliterative endarteritis and then tumor cells subsequently egress through vascular walls into the perivascular lymphatics.
- The second theory states there may be diffuse retrograde permeation and embolization of lymphatics after involvement of the hilar lymph nodes.
- Early clinical features include dyspnea, fatigue, and weight-loss.
- Lymphangitis carcinomatosa may precede or obscure or dominate any local symptoms and present as a diagnostic problem in dyspnoea.[16]
- Lymphangitis carcinomatosa may also occur during the evolution of a growth, which has already been identified during life, in which case diagnosis becomes relatively easier.
- If left untreated, patients with lymphangitis carcinomatosa may progress to develop acute respiratory failure.
- Common complications of lymphangitis carcinomatosa include:[9]
- Prognosis is generally poor, and the mean survival rate of patients after diagnosis of lymphangitis carcinomatosa is approximately 6 months.
- Approximately half of patients succumbing to their illness within a year of diagnosis.
- Occasionally, long-term survival is encountered.
Diagnosis
Symptoms
- The majority of patients with lymphangitis carcinomatosa are asymptomatic.
- Lymphangitis carcinomatosa is usually asymptomatic.[17]
- Symptoms of lymphangitis carcinomatosa may include the following:[13]
Physical Examination
- Patients with lymphangitis carcinomatosa usually appear pale and malnourished.
- Physical examination may be remarkable for:[13]
Auscultation
- Present pleural friction rub
- Present egophony
- Crackling or bubbling noises
- Present whispered pectoriloquy
- Decreased/absent breath sounds
Percussion
- Dull percussion
- Reduced chest expansion
Laboratory Findings
- There are no specific laboratory findings associated with lymphangitis carcinomatosa.[18]
- Even if histologically confirmed, the chest radiograph is normal in 30–50% of cases.
Imaging Findings
- Computed tomography is the imaging modality of choice for lymphangitis carcinomatosa.[13]
- The most important feature about CT scan is the detection of peripheral and central changes.
- On CT, characteristic findings of lymphangitis carcinomatosa include:[13]
- Subpleural nodules, and thickening on the interlobar fissures
- Pleural effusion
- Hilar and mediastinal nodal enlargement (40-50%)
- Relatively little destruction of overall lung architecture
- Involvement of the peripheral (interlobular septa) and central lymphatic system
- Distribution of changes is variable, but most are asymmetric and patchy
- Usually bilateral (may be unilateral especially in cases of lung and breast cancer)
- Radiographic appearances can most easily be divided into those due to the involvement of the peripheral and central lymphatic system.[19]
- Involvement may be diffusely of both, or predominantly of one compartment or the other.
- Distribution of changes is variable, but most are asymmetric and patchy; it is usually bilateral but may be unilateral, specifically in cases of lung and breast cancer.[20]
Treatment
Medical Therapy
- The mainstay therapy for lymphangitis carcinomatosa is systemic chemotherapy (chemotherapeutic regimen depends on the tumor histology).[13]
Surgery
Prevention
- There are no primary preventive measures available for lymphangitis carcinomatosa. [4]
- Once diagnosed and successfully treated, patients with lymphangitis carcinomatosa are followed-up periodically.
- Follow-up testing may include respiratory function tests and disease progression monitorization.
References
- ↑ Doyle, L (2018). "Gabriel Andral (1797-1876) and the First Reports of Lymphangitis Carcinomatosa". Journal of the Royal Society of Medicine. 82 (8): 491–493. doi:10.1177/014107688908200814. ISSN 0141-0768.
- ↑ Doyle, L (2018). "Gabriel Andral (1797-1876) and the First Reports of Lymphangitis Carcinomatosa". Journal of the Royal Society of Medicine. 82 (8): 491–493. doi:10.1177/014107688908200814. ISSN 0141-0768.
- ↑ Aslam HM, Zhi C, Nadeem M, Arsalan M, Wallach SL (April 2019). "A Case of Rapidly Deteriorating Lymphangitic Carcinomatosis in a Patient with Stage IV Pancreatic Cancer". Cureus. 11 (4): e4421. doi:10.7759/cureus.4421. PMC 6559437 Check
|pmc=value (help). PMID 31245208. - ↑ 4.0 4.1 Biswas, Abhishek; Sriram, Peruvemba S. (2015). "Getting the Whole Picture: Lymphangitic Carcinomatosis". The American Journal of Medicine. 128 (8): 837–840. doi:10.1016/j.amjmed.2015.04.007. ISSN 0002-9343.
- ↑ Beattie, J.W. (1956). "Lymphangitis carcinomatosa". British Journal of Tuberculosis and Diseases of the Chest. 50 (2): 120–129. doi:10.1016/S0366-0869(56)80046-4. ISSN 0366-0869.
- ↑ "Lymphangitic carcinomatosis | Radiology Reference Article | Radiopaedia.org".
- ↑ Moubax, Kim; Wuyts, Wim; Vandecaveye, Vincent; Prenen, Hans (2012). "Pulmonary lymphangitic carcinomatosis as a primary manifestation of gastric carcinoma in a young adult: a case report and review of the literature". BMC Research Notes. 5 (1): 638. doi:10.1186/1756-0500-5-638. ISSN 1756-0500.
- ↑ 8.0 8.1 8.2 Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis
- ↑ 9.0 9.1 Thomas, A.; Lenox, R. (2008). "Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult". Canadian Medical Association Journal. 179 (4): 338–340. doi:10.1503/cmaj.080142. ISSN 0820-3946.
- ↑ Aslam, Hafiz M; Zhi, Cassandra; Nadeem, Muhammad; Arsalan, Mohammad; Wallach, Sara L (2019). "A Case of Rapidly Deteriorating Lymphangitic Carcinomatosis in a Patient with Stage IV Pancreatic Cancer". Cureus. doi:10.7759/cureus.4421. ISSN 2168-8184.
- ↑ Thomas, A.; Lenox, R. (2008). "Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult". Canadian Medical Association Journal. 179 (4): 338–340. doi:10.1503/cmaj.080142. ISSN 0820-3946.
- ↑ Kashihara, Eriko; Kanai, Osamu; Okamura, Misato; Mio, Tadashi (2018). "Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome". BMJ Case Reports: bcr-2018–224206. doi:10.1136/bcr-2018-224206. ISSN 1757-790X.
- ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis
- ↑ Raja, Anand; Seshadri, Ramakrishnan Ayloor; Sundersingh, Shirley (2011). "Lymphangitis Carcinomatosa: Report of a Case and Review of Literature". Indian Journal of Surgical Oncology. 1 (3): 274–276. doi:10.1007/s13193-011-0047-9. ISSN 0975-7651.
- ↑ Khachekian, Arsineh; Shargh, Sean; Arabian, Sarkis (2015). "Pulmonary Lymphangitic Carcinomatosis From Metastatic Gastric Adenocarcinoma: Case Report". The Journal of the American Osteopathic Association. 115 (5): 332. doi:10.7556/jaoa.2015.064. ISSN 0098-6151.
- ↑ Jaswal, Sofia; Ahuja, Vanita; Aggarwal, Deepak; Kaur, Harkirat (2019). "Incidental finding of pulmonary lymphangitis carcinomatosa in a patient of chest trauma". Indian Journal of Anaesthesia. 63 (1): 70. doi:10.4103/ija.IJA_581_18. ISSN 0019-5049.
- ↑ Raja, Anand; Seshadri, Ramakrishnan Ayloor; Sundersingh, Shirley (2011). "Lymphangitis Carcinomatosa: Report of a Case and Review of Literature". Indian Journal of Surgical Oncology. 1 (3): 274–276. doi:10.1007/s13193-011-0047-9. ISSN 0975-7651.
- ↑ Gilchrist, F. J.; Alton, H.; Brundler, M.-A.; Edwards, L.; Plunkett, A.; Rao, S. (2011). "Pulmonary lymphangitic carcinomatosis presenting as severe interstitial lung disease in a 15-year-old female". European Respiratory Review. 20 (121): 208–210. doi:10.1183/09059180.00000911. ISSN 0905-9180.
- ↑ Munn, Lance L.; Padera, Timothy P. (2014). "Imaging the lymphatic system". Microvascular Research. 96: 55–63. doi:10.1016/j.mvr.2014.06.006. ISSN 0026-2862.
- ↑ Aburto, Myriam; Herráez, Inmaculada; Iturbe, David; Jiménez-Romero, Ana (2018). "Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis". Medical Sciences. 6 (3): 73. doi:10.3390/medsci6030073. ISSN 2076-3271.